• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Enstitüler
  • Kanser Enstitüsü
  • Kanser Enstitüsü Makale Koleksiyonu
  • View Item
  •   DSpace Home
  • Enstitüler
  • Kanser Enstitüsü
  • Kanser Enstitüsü Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Tamoxifen-Induced Tissue Factor Pathway Inhibitor Reduction: A Clue for an Acquired Thrombophilic State?

View/Open
licence.txt (242bytes)
1-s2.0-S0923753419475315-main.pdf (88.87Kb)
Date
2004
Author
Erman, M.
Abalı, H.
Oran, B.
Haznedaroğlu, İbrahim C.
Canpınar, H.
Kirazlı, S.
Çelik, İ.
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Background: Current understanding of hemostatic systems enables us to better explore the enigmatic pathobiology of tamoxifen (TAM)-induced thrombotic diathesis. We have therefore aimed to assess the hemostatic changes in breast cancer patients receiving TAM on an adjuvant basis. Patients and methods: The study population consisted of 43 female patients with hormone receptor-positive breast cancer who received TAM 20 mg/day as part of their adjuvant treatment. Mean age was 52+/-12 years (range 25-74). Twenty-one patients (49%) were premenopausal. Plasma samples were collected prior to and following 6 months of TAM therapy and were assayed for total tissue factor pathway inhibitor (TFPI), free TFPI, lipid-bound TFPI, thrombomodulin, D dimer, activated protein C resistance (APC res), factors VIIa, II, V, VII and X, and global fibrinolytic capacity (GFC). Results: Median total TFPI decreased significantly from 48.5 ng/ml to 36.2 ng/ml (P=0.001), free TFPI from 10 to 7.6 ng/ml (P=0.001) and lipid-bound TFPI from 39.1 to 28.7 ng/ml (P=0.001). There were significant decreases in the levels of factor 11 (P=0.03), factor V (P=0.001), factor VII (P=0.06), thrombomodulin (P=0.01) and D dimer (P=0.001). However, APC res times were significantly prolonged (P=0.04). The remaining parameters that we have studied were not significantly affected. Conclusion: Our findings suggest that TAM tends to activate the coagulation pathway by counteracting major molecules involved in coagulation inhibition, namely TFPI and TM. As reflected by unchanged GFC, the drug appears to impair the expected compensatory activation of the fibrinolytic system, which removes fibrin polymers resulting from coagulation activation.
URI
https://doi.org/10.1093/annonc/mdh437
http://hdl.handle.net/11655/22217
xmlui.mirage2.itemSummaryView.Collections
  • Kanser Enstitüsü Makale Koleksiyonu [40]
Hacettepe Üniversitesi Kütüphaneleri
Açık Erişim Birimi
Beytepe Kütüphanesi | Tel: (90 - 312) 297 6585-117 || Sağlık Bilimleri Kütüphanesi | Tel: (90 - 312) 305 1067
Bizi Takip Edebilirsiniz: Facebook | Twitter | Youtube | Instagram
Web sayfası:www.library.hacettepe.edu.tr | E-posta:openaccess@hacettepe.edu.tr
Sayfanın çıktısını almak için lütfen tıklayınız.
Contact Us | Send Feedback



DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV
 

 


DSpace@Hacettepe
huk openaire onayı
by OpenAIRE

About HUAES
Open Access PolicyGuidesSubcriptionsContact

livechat

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtype

My Account

LoginRegister

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV